New research has found that around 20% of cervical cancer cases diagnosed in the UK each year are in women aged over 65, sparking calls for an extension to screening services.
News
Drugmakers omit detail on FDA drug rejections, study finds
Pharmaceutical companies are holding back information from the public on why their medicines have been rejected by the US Food and Drug Administration, a study published in the BMJ has found.
Higher dose of AZ’ gout drug hits PhIII goals
AstraZeneca has reported data from a Phase III trial showing that its investigational gout drug lesinurad hit primary targets by reducing a key marker of the condition, but only at the higher dose.
Novartis considers filing Arzerra for relapsed CLL on strong data
Novartis is evaluating a potential regulatory filing for Arzerra in relapsed chronic lymphocytic leukaemia after the drug was shown to significantly increase progression-free survival in a Phase III trial.
CCG dumps seven-day GP pilot on lack of demand
NHS Hambleton, Richmondshire and Whitby Clinical Commissioning Group has suspended a pilot testing seven-day access to GP services because of a lack of patient demand.
Fantastic new venue confirmed for PharmaTimes Sales Awards 2015
Organiser PharmaTimes Media is delighted to announce the new venue for the Sales Awards and the Medical Science Liaison of the Year competition.
FDA clears Novartis’ Promacta for paediatric ITP patients
The US Food and Drug Administration has expanded the scope of Novartis’ immune thrombocytopenia drug Promacta to treat children with the rare clotting disorder.
FDA panel unanimously backs GSKs asthma biologic
GlaxoSmithKline’s non-inhaled, biologic therapy for a difficult-to-treat form of severe asthma is now a hair’s breadth away from US approval after regulatory advisors unanimously backed its use in adults, but not adolescents.
MSF urges India not to bow to patent pressure
Médecins Sans Frontières is urging the Indian government to not relax its drug patent laws and keep the country as a source of cheap medicines.
Call for adaptive licensing to smash UK cancer drugs bottle-neck
The rejection of yet another promising cancer drug by NHS cost regulators has sparked a renewed call for reform of the system and the introduction of adaptive licensing to help speed up patient access to innovative medicines.
FDA panel also backs Amgen’s PCSK9 inhibitor
Amgen will be breathing a huge sigh of relief after US regulatory advisors recommended approval of its cholesterol-buster Repatha, just a day after backing Sanofi/Regeneron’s rival PCSK9 inhibitor Praluent.
NHS could save £5bn a year through minor reforms, finds review
The NHS could be saving £5 billion a year by 2020 with better use of staff and medicines and more efficient processes and systems in general, according to findings of an interim report by Lord Carter.
Pfizer’s Pristiq fails in paediatric study
Pfizer’s Pristiq has failed to hit its primary target in a post-marketing trial involving paediatric patients with major depressive disorder.
Real world data back safety, efficacy of Remicade biosimilar
New data out this week support the use of Hospira’s biosimilar Inflectra as a potentially cost-effective treatment option for patients with rheumatic diseases, offering comparable quality, efficacy and safety to reference blockbuster drug Remicade.
Roche’s Actemra gets US breakthrough status for systemic sclerosis
The US Food and Drug Administration has assigned Roche’s Actemra breakthrough status for systemic sclerosis, potentially speeding up its development and review for this indication.
